首页> 美国卫生研究院文献>Turkish Journal of Hematology >The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia

【2h】

The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia

机译：可溶性尿激酶纤溶酶原激活物受体在急性髓样白血病中的预后意义

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objective:The soluble urokinase plasminogen activator receptor (suPAR) is a soluble form of the urokinase plasminogen activator receptor expressed in various immune and cancer cells. The levels of suPAR have been demonstrated to correlate with prognosis in various cancers. This study was intended to investigate serum suPAR levels and their effect on prognosis in patients with acute myeloid leukemia (AML).

机译：目的：可溶性尿激酶纤溶酶原激活剂受体（suPAR）是在各种免疫细胞和癌细胞中表达的可溶性尿激酶纤溶酶原激活剂受体。已经证明suPAR的水平与多种癌症的预后相关。这项研究旨在调查血清suPAR水平及其对急性髓细胞性白血病（AML）患者预后的影响。

著录项

期刊名称 Turkish Journal of Hematology
作者
Nergiz Erkut; Ahmet Menteşe; Hasan Mücahit Özbaş; Nilay Ermantaş; Ayşegül Sümer; Asım Örem; Mehmet Sönmez;
展开▼
作者单位

展开▼
年(卷),期 2016(33),2
年度 2016
页码 135–140
总页数 6
原文格式 PDF
正文语种
中图分类血液学检验;
关键词
Soluble urokinase plasminogen activator receptor Acute myeloid leukemia prognosis;

机译：可溶性尿激酶纤溶酶原激活物受体;急性髓细胞性白血病;预后;

相似文献

外文文献
中文文献
专利

1. The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia [J] . Nergiz Erkut, Ahmet Mente?e, Hasan Mücahit ?zba?, Turkish Journal of Hematology . 2016,第2期

机译：可溶性尿激酶纤溶酶原激活物受体在急性髓样白血病中的预后意义
2. Role of urokinase plasminogen activator receptor (CD87) as a prognostic marker in acute myeloid leukemia. [J] . Maha Atfy, Mohamad Eissa, Hossam E Salah, Medical oncology . 2012,第3期

机译：尿激酶纤溶酶原激活剂受体（CD87）作为急性髓细胞性白血病的预后标志物的作用。
3. Urokinase plasminogen activator receptor and soluble matrix metalloproteinase-9 in acute myeloid leukemia patients: a possible relation to disease invasion. [J] . Aref S, El Sherbiny M, Mabed M, Hematology. . 2003,第6期

机译：急性髓细胞性白血病患者的尿激酶纤溶酶原激活剂受体和可溶性基质金属蛋白酶9：可能与疾病侵袭有关。
4. Inhibition of the Tumor-Associated Urokinase-Type Plasminogen Activation System: Effects of High-Level Synthesis of Soluble Urokinase Receptor in Ovarian and Breast Cancer Cells In Vitro and In Vivo [C] . Viktor Magdolen International Meeting on Molecular Staging on Cancer . 2003

机译：抑制肿瘤相关的尿激酶型纤溶酶原激活系统：高水平合成在体外和体内卵巢癌细胞中可溶性尿激酶受体的影响
5. Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study [D] . Harada Yasuhiko, 原田靖彦 2019

机译：根据2017年日本成人白血病研究组（JALSG）AML201研究治疗的成人急性髓性白血病患者的遗传学预测，根据2017 ELN风险分层进行预后分析
6. Soluble urokinase-type plasminogen activator receptor and urokinase-type plasminogen activator receptor contribute to chemoresistance in leukemia [O] . Hong Guo, Lan-Xia Zhou, Haizhen Ma, -1

机译：可溶性尿激酶型纤溶酶原激活物受体和尿激酶型纤溶酶原激活物受体有助于白血病的化学耐药性
7. The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia [O] . Nergiz Erkut, Ahmet Menteşe, Hasan Mücahit Özbaş 2016

机译：可溶性尿激酶型纤溶酶原激活物受体在急性髓系白血病中的预后意义

The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia

摘要

著录项

相似文献

相关主题

期刊订阅